Leading Companies Reinforcing Their Presence in the Peptide Therapeutics Market

The peptide therapeutics sector is on track for remarkable growth over the coming years, driven by advancements in personalized medicine and innovative drug development techniques. This market is becoming increasingly important as new technologies and expanded healthcare needs fuel demand for peptide-based treatments. Let's explore the market's valuation forecasts, key players, emerging trends, and core segments shaping its future.

Projected Expansion and Market Size of the Peptide Therapeutics Market
The peptide therapeutics market is anticipated to expand rapidly and reach a valuation of $83.57 billion by 2030. This remarkable growth corresponds to a compound annual growth rate (CAGR) of 11.2%. Several factors are driving this surge, including the rise of personalized medicine, heightened investments in peptide-based therapies, the integration of artificial intelligence in drug discovery, growth in biologics manufacturing, and expanding healthcare markets in emerging economies. Key trends shaping the market include the development of targeted peptide drugs, innovations in peptide delivery methods, multifunctional peptide therapeutics, natural peptide extraction and synthesis techniques, as well as combination therapies involving peptides.

Download a free sample of the peptide therapeutics market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7216&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Players Influencing the Peptide Therapeutics Industry
The peptide therapeutics landscape features several leading pharmaceutical and biotechnology companies. Notable participants include Pfizer Inc., Johnson & Johnson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., and Bachem Holding AG. Additionally, specialized firms such as PolyPeptide Laboratories BV, Arcus Biosciences Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., and Merck & Co Inc. contribute significantly to this market's development.

Strategic Moves Highlighted by AstraZeneca's Acquisition
In July 2024, AstraZeneca plc, headquartered in England, finalized the acquisition of Amolyt Pharma for $1.05 billion. This move aligns with AstraZeneca's strategy to bolster its presence in rare disease therapeutics and expand its portfolio in high-need treatment areas. Amolyt Pharma, a clinical-stage biotech firm based in France, focuses on developing therapeutic peptides targeting rare endocrine and metabolic disorders, thereby complementing AstraZeneca's ambitions in specialized peptide-based therapies.

View the full peptide therapeutics market report:
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Advancements and Innovations Driving the Peptide Therapeutics Market
Leading companies in the peptide therapeutics sector are investing in cutting-edge technologies such as cell culture processes to enhance competitiveness. Cell culture involves growing cells outside their natural environment under controlled conditions, allowing for precise manipulation and optimization. For example, in June 2023, Evonik Industries AG, a German specialty chemicals company, introduced cQrex KC-a next-generation peptide designed to improve cell culture processes in biopharmaceutical manufacturing. This product helps optimize cystine supply, boost cell productivity, and supports the development of vaccines, viral vectors, and cell therapies, highlighting the innovative strides being made in the field.

Core Segments within the Peptide Therapeutics Market
The market is categorized into several key segments for comprehensive analysis. By type, it includes generic peptides and branded peptides. In terms of administration routes, the categories cover parenteral, mucosal, oral, and transdermal delivery methods. The application spectrum spans cancer, cardiovascular diseases, central nervous system disorders, metabolic diseases, infections, hematological disorders, gastrointestinal conditions, dermatology, respiratory ailments, acromegaly, and other therapeutic areas. Further subsegments include generic peptides divided into generic peptide drugs and biosimilars, and branded peptides classified as innovative peptide drugs and patent-protected peptides.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.